Entrada Therapeutics Appoints Mario Saltarelli, M.D., Ph.D., as Chief Medical Officer
Mass., March 19, 2019 – Entrada Therapeutics,
a biotechnology company dedicated to transforming the treatment of devastating
diseases through the intracellular delivery of biologics, today announced the
appointment of Mario Saltarelli, M.D., Ph.D., as Chief Medical Officer. Dr. Saltarelli
was most recently Executive Vice President and Chief Medical Officer at Syntimmune and joins Entrada following more than
30 years in the biomedical and biopharmaceutical sectors.
“With his extensive industry expertise and track record of building successful pipelines and leading drug development organizations across multiple therapeutic areas, Mario is the ideal person to serve as our Chief Medical Officer,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. “Mario’s background spans all areas of pharmaceutical and regulatory science, from preclinical through post-market development. His experiences at both venture-backed biotechnology and global pharmaceutical companies have involved him in every aspect of bringing a medicine from bench to bedside. I know Mario will be instrumental as we advance our intracellular biologics programs and I am pleased to welcome him to the Entrada executive team.”
While serving as Executive Vice President and Chief Medical Officer at Syntimmune, a biotechnology company developing therapeutics for rare autoimmune diseases, Dr. Saltarelli directed the company’s overall pipeline and program strategy. Dr. Saltarelli was responsible for all development and regulatory activities for SYNT001, an anti-FcRn monoclonal antibody, currently in Phase II clinical trials for pemphigus and warm autoimmune hemolytic anemia, as well as under preclinical investigation for neurological autoimmune diseases. Syntimmune was acquired by Alexion Pharmaceuticals in November 2018.
Prior to joining Syntimmune, Dr. Saltarelli was Senior Vice President at Vertex Pharmaceuticals, where he led the Early Development and Neurology organizations and contributed to multiple R&D committees. Prior to Vertex, Dr. Saltarelli served as Chief Medical Officer of Annexon Biosciences, a biotechnology company developing anti-complement therapeutics for neurological and ophthalmological diseases. Dr. Saltarelli previously held executive leadership positions at Mallinckrodt Pharmaceuticals, Shire, Abbott Laboratories (now AbbVie) and Pfizer. Prior to entering the pharmaceutical industry, Dr. Saltarelli was Assistant Professor of Neurology at Emory University School of Medicine in Atlanta. Dr. Saltarelli earned both an M.D. and a Ph.D. in neuroscience from The Johns Hopkins University School of Medicine in Baltimore and completed neurology residency training at The Johns Hopkins Hospital.
“I am delighted to be joining Entrada during this exciting period in the Company’s growth,” said Dr. Saltarelli. “A substantial opportunity exists to use Entrada’s intracellular delivery technology to bring innovative therapies to patients suffering from rare and debilitating diseases. I look forward to working with the entire team as we fully realize the potential of the Entrada platform for the benefit of patients.”
About Entrada Therapeutics
Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company’s novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.
Russo Partners, LLC